Rheumatology
| Spondyloarthritis Including Psoriatic Arthritis
Rheumatology
Spondyloarthritis Including Psoriatic Arthritis

Efficacy and safety of ixekizumab versus adalimumab with and without concomitant conventional synthetic disease-modifying antirheumatic drugs (DMARD) in biologic DMARD-naïve patients with psoriatic arthritis: 52-week results

book_2 Source: ACR Convergence 2020 - Poster session - Abs #0352
calendar_today Published on Medfyle: November 2020
headphones 2 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • A subanalysis of the SPIRIT-H2H trial was conducted to explore how concomitant use of conventional synthetic (cs)DMARDs may affect the efficacy and safety of ixekizumab and adalimumab, by stratifying patients according to csDMARD use at baseline.
  • At Week 52, the proportion of patients achieving ACR50 response was comparable between ixekizumab and adalimumab, and independent of concomitant csDMARD use.
  • Ixekizumab monotherapy allowed a higher proportion of patients to achieve minimal disease activity compared to adalimumab, but this was no longer evident for the combination therapy.
  • No safety issues were observed in any of the treatment groups.
Presenting Author
Read more arrow_downward Hide arrow_upward

Josef Smolen, MD
Medical University of Vienna
Vienna, Austria

Josef Smolen received his MD degree from the University of Vienna, Austria, and trained there in Immunology, Medicine and Rheumatology. He was a research fellow at the Arthritis Institute at NIH, Bethesda, MD, USA. From 1989 to 2017 he has been Chairman, 2nd Department of Medicine, Hietzing Hospital, Vienna; 1995-2018 he served as Professor of Medicine and Chairman, Division of Rheumatology, Medical University of Vienna, where he also acted as Chairman of the Department of Medicine 3 from 2007 to 2018. He is now Emeritus Professor of Medicine at the Medical University of Vienna, Austria. An author of several hundred original publications and lead investigator of many clinical trials, his major scientific interests concern elucidation of the pathogenesis of rheumatic diseases, translational research, outcomes and epidemiologic research, as well as novel therapies and therapeutic strategies in rheumatic diseases. Josef Smolen was President of EULAR from 2003 to 2005 and President of the Austrian Society of Rheumatology and Austrian Society of Immunology. He is a member of the Austrian Academy of Sciences, the German Academy of Sciences (Leopoldina), Fellow of the Royal College of Physicians (London) and Honorary Doctor of Lund University, Sweden, Leiden University, Netherlands, and Semmelweis University, Budapest. He is a co-editor of the textbook “Rheumatology” whose 8th edition is in preparation. He currently serves as editor-in-chief of Annals of the Rheumatic Diseases.

Presenter disclosures
Read more arrow_downward Hide arrow_upward

J. Smolen, AbbVie, AstraZeneca, Eli Lilly, Celgene, Celltrion, Chugai, Gilead , ILTOO , Janssen, Kabi, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi


Feedback